Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1625 1629 4125
This examiner grants 54% of resolved cases
Gillian A Hutter is an examiner in Tech Center 4100, assigned to Art Unit 1625. The examiner has 121 resolved cases, which provides a solid statistical foundation for analysis. The data reveals an allowance rate of 54.5 percent, suggesting a moderate level of difficulty for applicants. This 54.5 percent rate is the primary baseline for prosecution in this docket.
The median time to allowance is 1077 days. Practitioners should prepare for a prosecution cycle of approximately 1077 days when working with this examiner. While the 54.5 percent allowance rate indicates that success is achieved in more than half of the cases, the 1077-day duration is a key factor in long-term planning. These metrics offer a clear picture of the typical experience in Art Unit 1625.
The interview lift is 46.2 percent, which is a very high figure. This 46.2 percent lift suggests that interviews are an extremely effective way to move a case toward allowance. By engaging in an interview, practitioners can nearly double their chances of success compared to the baseline. Given the 121 resolved cases, this 46.2 percent lift is a reliable indicator that direct communication is a winning strategy in Tech Center 4100.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17937948 | COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHAN | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 17837224 | COMPOSITIONS AND METHODS FOR INCREASING CELL SURFACE OXYTOCIN RECEPTOR (OXTR) | Final Rejection | Washington University |
| 19294542 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | Final Rejection | Sun Pharmaceutical Industries, Inc. |
| 18073181 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18603554 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | Final Rejection | Xenon Pharmaceuticals Inc. |
| 17294829 | COMPOSITION FOR STABILIZING POORLY SOLUBLE INGREDIENTS AND COSMETIC COMPOSITION COMPRISING SAME | Final Rejection | LG HOUSEHOLD & HEALTH CARE LTD. |
| 18901200 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | Non-Final OA | Florida State University Research Foundation, Inc. |
| 18065073 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | Final Rejection | Florida State University Research Foundation, Inc. |
| 17918973 | ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE | Non-Final OA | Genzyme Corporation |
| 18009645 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | Final Rejection | The Children's Medical Center Corporation |
| 18665688 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | Non-Final OA | GlaxoSmithKline Intellectual Property (No.3) Limited |
| 17764193 | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS AND USE THEREOF | Non-Final OA | Prime Reach Trading Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy